Corrigendum: Morphine Binds Creatine Kinase B and Inhibits Its Activity
- 1Institut des Neurosciences Cellulaires et Intégratives, CNRS UPR3212 and Université de Strasbourg, Strasbourg, France
- 2Laboratoire de Spectrométrie de Masse BioOrganique, IPHC-DSA, CNRS UMR7178 and Université de Strasbourg, Strasbourg, France
- 3CNRS UMR7177 and Université de Strasbourg, Strasbourg, France
- 4Mass Spectrometry Facilities of the CNRS UPR3212, Strasbourg, France
- 5School of Pharmacy, University of Queensland, PACE, Woolloongabba, QLD, Australia
A Corrigendum on
Morphine Binds Creatine Kinase B and Inhibits Its Activity
by Weinsanto, I., Mouheiche, J., Laux-Biehlmann, A., Delalande, F., Marquette, A., Chavant, V., et al. (2018). Front. Cell. Neurosci. 12:464. doi: 10.3389/fncel.2018.00464
In the published article, there was an error in affiliation “2.” Instead of “Global Drug Discovery, Global Therapeutic Research Groups, Gynecological Therapies, Bayer Healthcare, Berlin, Germany”, it should be “Laboratoire de Spectrométrie de Masse BioOrganique, IPHC-DSA, CNRS UMR7178 and Université de Strasbourg, Strasbourg, France.”
Additionally, the current address of one author has been added as a footnote and is denoted using “‡.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: morphine, complex, ligand-binding protein, creatine kinase, high affinity
Citation: Weinsanto I, Mouheiche J, Laux-Biehlmann A, Delalande F, Marquette A, Chavant V, Gabel F, Cianferani S, Charlet A, Parat M-O and Goumon Y (2019) Corrigendum: Morphine Binds Creatine Kinase B and Inhibits Its Activity. Front. Cell. Neurosci. 13:292. doi: 10.3389/fncel.2019.00292
Received: 13 June 2019; Accepted: 14 June 2019;
Published: 02 July 2019.
Approved by:Frontiers Editorial Office, Frontiers Media SA, Switzerland
Copyright © 2019 Weinsanto, Mouheiche, Laux-Biehlmann, Delalande, Marquette, Chavant, Gabel, Cianferani, Charlet, Parat and Goumon. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yannick Goumon, firstname.lastname@example.org
†These authors have contributed equally to this work
‡Present Address: Alexis Laux-Biehlmann, Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany